Liquid Biopsy Market Size & Forecast By Application (Therapy Selection for Metastatic Breast Cancer (MBS), Therapy Selection for Other Metastatic Cancers, Molecular Monitoring, Molecular Monitoring), By Sample Type (Blood, Urine, Tissue & Saliva), By Biomarker Type (Circulating Tumor Cells (CTC), Circulating Tumor DNA (ctDNA), Exosomes), By Technology (Single Gene Analysis (PCR Microarrays), Multi-gene-parallel Analysis (NGS)) And Trend Analysis from 2013 To 2030
Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant challenges associated with conventional biopsies such as, high level of invasiveness, incompleteness of cancer information that is acquired, associated post-biopsy serious medical complications, and subsequent cost inclusions. A growing need for more advanced, efficient and accurate method which provides a holistic view of the tumor and metastasis is the prime factor fueling rapid development of liquid biopsies.
The market has gained considerable traction in the past couple of years. A number of clinical research projects related to circulating tumor cells, and cell-free tumor DNA have been initiated in the latter half of the past decade. As a result, there are a number of ongoing clinical trials that are due to be completed between post 2017-18. It is expected that upon successful completion, commercialization of these assays and tests will provide the market a significant boost in potential addressable target revenue and fuel growth through to 2030.
Further key findings from the report suggest:
In terms of applications, therapy selection of metastatic cancers is the key area of liquid biopsy usage as these provide significant insights into the unique genetic information encoded in CTCs and ctDNAs. Furthermore, with the addition of more research data reinforcing the usage of liquid biopsies over the coming years, it is expected that their application for molecular monitoring of diseases will also be a lucrative source of revenue through to 2030
Key biomarkers that any liquid biopsy targets include circulating tumor cells, circulating tumor DNA and exosomes that are macrovesicles containing tumor RNA, or tumor protein freely circulating in the patient’s bloodstream. Assays for ctDNA are expected to account for the largest share of revenue through to 2030 owing to the currently present assays and expected number of products that are to be commercialized over the coming decade.
Development of parallel multi-gene analysis using next generation sequencing technology is the underlying factor that has enabled oncologists to more efficiently sequence ctDNA and gain insights related to cancer metastasis and the related mechanism. This understanding provides a patient-centric systemic view of cancer and aids in its long term monitoring.
North America, specifically the U.S. accounts for the largest share of revenue for the development of liquid biopsy market. The region was observed to account for around 50% of the global potential in 2015 owing to the high number clinical development projects underway for the commercialization of CTC and ctDNA assays till 2020. Furthermore, throughout the forecast period, U.S. is expected to dominate revenue generation owing to the dynamic nature & being the region of prime activity, research and development with respect to liquid biopsy and next generation sequencing technology.
Although, post successful commercialization through to 2030, Asia Pacific is expected to be a lucrative region for development as it is expected to be characterized by the presence of a large patient population base, developing healthcare framework and growth in integration of more advanced healthcare practices.
The market is in its developing phase and is characterized by the presence of a number of relatively smaller entities involved in innovation and new product development. Companies such as Biocept, Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Qiagen, Personal Genome Diagnostics, Cynvenio, RainDance Technologies, and Trovagene are operating in the space and have a number of commercialized assays in their portfolios for liquid biopsy.
Furthermore, as this space has a high lucrative potential, and is considerably influenced by the developments in NGS technology, there are a number of major players that have ongoing investigational & observational clinical trials and are due to be completed by 2017 to 2019. Collectively, over 30 clinical trials are currently registered as active by companies including Illumina, Foundation Medicine, Natera Inc., Roche, Sequenom, LabCorp, Epic Sciences, and Pathway Genomics in the U.S. alone. Anticipated successful commercialization of these products is expected to fuel growth over the forecast period.
The market has gained considerable traction in the past couple of years. A number of clinical research projects related to circulating tumor cells, and cell-free tumor DNA have been initiated in the latter half of the past decade. As a result, there are a number of ongoing clinical trials that are due to be completed between post 2017-18. It is expected that upon successful completion, commercialization of these assays and tests will provide the market a significant boost in potential addressable target revenue and fuel growth through to 2030.
Further key findings from the report suggest:
In terms of applications, therapy selection of metastatic cancers is the key area of liquid biopsy usage as these provide significant insights into the unique genetic information encoded in CTCs and ctDNAs. Furthermore, with the addition of more research data reinforcing the usage of liquid biopsies over the coming years, it is expected that their application for molecular monitoring of diseases will also be a lucrative source of revenue through to 2030
Key biomarkers that any liquid biopsy targets include circulating tumor cells, circulating tumor DNA and exosomes that are macrovesicles containing tumor RNA, or tumor protein freely circulating in the patient’s bloodstream. Assays for ctDNA are expected to account for the largest share of revenue through to 2030 owing to the currently present assays and expected number of products that are to be commercialized over the coming decade.
Development of parallel multi-gene analysis using next generation sequencing technology is the underlying factor that has enabled oncologists to more efficiently sequence ctDNA and gain insights related to cancer metastasis and the related mechanism. This understanding provides a patient-centric systemic view of cancer and aids in its long term monitoring.
North America, specifically the U.S. accounts for the largest share of revenue for the development of liquid biopsy market. The region was observed to account for around 50% of the global potential in 2015 owing to the high number clinical development projects underway for the commercialization of CTC and ctDNA assays till 2020. Furthermore, throughout the forecast period, U.S. is expected to dominate revenue generation owing to the dynamic nature & being the region of prime activity, research and development with respect to liquid biopsy and next generation sequencing technology.
Although, post successful commercialization through to 2030, Asia Pacific is expected to be a lucrative region for development as it is expected to be characterized by the presence of a large patient population base, developing healthcare framework and growth in integration of more advanced healthcare practices.
The market is in its developing phase and is characterized by the presence of a number of relatively smaller entities involved in innovation and new product development. Companies such as Biocept, Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Qiagen, Personal Genome Diagnostics, Cynvenio, RainDance Technologies, and Trovagene are operating in the space and have a number of commercialized assays in their portfolios for liquid biopsy.
Furthermore, as this space has a high lucrative potential, and is considerably influenced by the developments in NGS technology, there are a number of major players that have ongoing investigational & observational clinical trials and are due to be completed by 2017 to 2019. Collectively, over 30 clinical trials are currently registered as active by companies including Illumina, Foundation Medicine, Natera Inc., Roche, Sequenom, LabCorp, Epic Sciences, and Pathway Genomics in the U.S. alone. Anticipated successful commercialization of these products is expected to fuel growth over the forecast period.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
CHAPTER 3. MARKET SNAPSHOT
CHAPTER 4. MARKET VARIABLES, TRENDS & SCOPE
4.1. Market Segmentation & Scope
4.2. Market Driver Analysis
4.3. Market Restraint Analysis
4.4. Penetration & Growth Prospect Mapping
4.5. SWOT Analysis, By Factor
4.5.1. Political
4.5.2. Economic
4.5.3. Technological
4.6. Industry Analysis - Porter’s
4.7. Competitive Landscape & Market Share Analysis, 2015 & 2030
4.8. Liquid Biopsy Pipeline Analysis, 2015 - 2020
CHAPTER 5. MARKET CATEGORIZATION 1: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Movement Analysis & Market Share, 2015, 2020 & 2030
5.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following applications:
5.2.1. Therapy Selection for Metastatic Breast Cancer (MBS)
5.2.2. Therapy Selection for Other Metastatic Cancer
5.2.3. Molecular Health Monitoring
CHAPTER 6. MARKET CATEGORIZATION 2: SAMPLE TYPE ESTIMATES & TREND ANALYSIS
6.1. Sample Type Movement Analysis & Market Share, 2015, 2020 & 2030
6.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following sample types:
6.2.1. Blood Samples
6.2.2. Urine Samples
6.2.3. Other Bio fluids (Tissue fluids and Saliva)
CHAPTER 7. MARKET CATEGORIZATION 3: BIOMARKER ESTIMATES & TREND ANALYSIS
7.1. Biomarker Movement Analysis & Market Share, 2015, 2020 & 2030
7.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following biomarkers:
7.2.1. Circulating Tumor Cells (CTC)
7.2.2. Circulating Tumor DNA (ctDNA)
7.2.3. Exosomes (Macrovesicles with Protein, RNA, DNA)
CHAPTER 8. MARKET CATEGORIZATION 4: TECHNOLOGY ESTIMATES & TREND ANALYSIS
8.1. Technology Movement Analysis & Market Share, 2015, 2020 & 2030
8.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following technologies:
8.2.1. Multi-gene parallel Analysis using NGS
8.2.2. Single Gene Analysis using PCR Microarrays
CHAPTER 9. MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Movement Analysis & Market Share, 2015, 2020 & 2030
9.2. North America
9.2.1. North America revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. North America revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.2.2.1. U.S.
9.2.2.2. Canada
9.2.3. North America revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.2.3.1. U.S.
9.2.3.2. Canada
9.2.4. North America revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.2.4.1. U.S.
9.2.4.2. Canada
9.3. Europe
9.3.1. Europe revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.3.1.1. Germany
9.3.1.2. UK
9.3.2. Europe revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.3.2.1. Germany
9.3.2.2. UK
9.3.3. Europe revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.3.3.1. Germany
9.3.3.2. UK
9.3.4. Europe revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.3.4.1. Germany
9.3.4.2. UK
9.4. Asia Pacific
9.4.1. Asia Pacific revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.4.1.1. Japan
9.4.1.2. China
9.4.2. Asia Pacific revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.4.2.1. Japan
9.4.2.2. China
9.4.3. Asia Pacific revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.4.3.1. Japan
9.4.3.2. China
9.4.4. Asia Pacific revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.4.4.1. Japan
9.4.4.2. China
9.5. Latin America
9.5.1. Latin America revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.5.1.1. Brazil
9.5.2. Latin America revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.5.2.1. Brazil
9.5.3. Latin America revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.5.3.1. Brazil
9.5.4. Latin America revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.5.4.1. Brazil
9.6. Middle East & Africa
9.6.1. Middle East & Africa revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.6.1.1. South Africa
9.6.2. Middle East & Africa revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.6.2.1. South Africa
9.6.3. Middle East & Africa revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.6.3.1. South Africa
9.6.4. Middle East & Africa revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.6.4.1. South Africa
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Adaptive Biotechnologies
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiatives
10.2. Biocept
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Strategic Initiatives
10.3. Guardant Health
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Strategic Initiatives
10.4. NeoGenomics Laboratories
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Strategic Initiatives
10.5. Personal Genome Diagnostics
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Strategic Initiatives
10.6. Qiagen
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Strategic Initiatives
10.7. RainDance Technologies
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Strategic Initiatives
10.8. Trovagene
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Strategic Initiatives
10.9. Cynvenio
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Strategic Initiatives
10.10. Epic Sciences
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Strategic Initiatives
10.11. Exosome
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Strategic Initiatives
10.12. Foundation Medicine
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Strategic Initiatives
10.13. Genomic Health
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Strategic Initiatives
10.14. Illumina Inc.
10.14.1. Company Overview
10.14.2. Financial Performance
10.14.4. Strategic Initiatives
10.15. Angle Plc
10.15.1. Company Overview
10.15.2. Financial Performance
10.15.3. Product Benchmarking
10.15.4. Strategic Initiatives
10.16. Boreal Genomics
10.16.1. Company Overview
10.16.2. Financial Performance
10.16.3. Product Benchmarking
10.16.4. Strategic Initiatives
10.17. CareDx
10.17.1. Company Overview
10.17.2. Financial Performance
10.17.3. Product Benchmarking
10.17.4. Strategic Initiatives
10.18. Chronix Biomedical
10.18.1. Company Overview
10.18.2. Financial Performance
10.18.3. Product Benchmarking
10.18.4. Strategic Initiatives
10.19. Cynvenio Biosystems Inc.
10.19.1. Company Overview
10.19.2. Financial Performance
10.19.3. Product Benchmarking
10.19.4. Strategic Initiatives
10.20. Epic Sciences
10.20.1. Company Overview
10.20.2. Financial Performance
10.20.3. Product Benchmarking
10.20.4. Strategic Initiatives
10.21. Foundation Medicine
10.21.1. Company Overview
10.21.2. Financial Performance
10.21.3. Product Benchmarking
10.21.4. Strategic Initiatives
10.22. Natera Inc.
10.22.1. Company Overview
10.22.2. Financial Performance
10.22.3. Product Benchmarking
10.22.4. Strategic Initiatives
10.23. Pathway Genomics
10.23.1. Company Overview
10.23.2. Financial Performance
10.23.3. Product Benchmarking
10.23.4. Strategic Initiatives
10.24. Roche (Ariosa)
10.24.1. Company Overview
10.24.2. Financial Performance
10.24.3. Product Benchmarking
10.24.4. Strategic Initiatives
10.25. Sequenom
10.25.1. Company Overview
10.25.2. Financial Performance
10.25.3. Product Benchmarking
10.25.4. Strategic Initiatives
10.26. Trovagene
10.26.1. Company Overview
10.26.2. Financial Performance
10.26.3. Product Benchmarking
10.26.4. Strategic Initiatives
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
CHAPTER 3. MARKET SNAPSHOT
CHAPTER 4. MARKET VARIABLES, TRENDS & SCOPE
4.1. Market Segmentation & Scope
4.2. Market Driver Analysis
4.3. Market Restraint Analysis
4.4. Penetration & Growth Prospect Mapping
4.5. SWOT Analysis, By Factor
4.5.1. Political
4.5.2. Economic
4.5.3. Technological
4.6. Industry Analysis - Porter’s
4.7. Competitive Landscape & Market Share Analysis, 2015 & 2030
4.8. Liquid Biopsy Pipeline Analysis, 2015 - 2020
CHAPTER 5. MARKET CATEGORIZATION 1: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Movement Analysis & Market Share, 2015, 2020 & 2030
5.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following applications:
5.2.1. Therapy Selection for Metastatic Breast Cancer (MBS)
5.2.2. Therapy Selection for Other Metastatic Cancer
5.2.3. Molecular Health Monitoring
CHAPTER 6. MARKET CATEGORIZATION 2: SAMPLE TYPE ESTIMATES & TREND ANALYSIS
6.1. Sample Type Movement Analysis & Market Share, 2015, 2020 & 2030
6.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following sample types:
6.2.1. Blood Samples
6.2.2. Urine Samples
6.2.3. Other Bio fluids (Tissue fluids and Saliva)
CHAPTER 7. MARKET CATEGORIZATION 3: BIOMARKER ESTIMATES & TREND ANALYSIS
7.1. Biomarker Movement Analysis & Market Share, 2015, 2020 & 2030
7.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following biomarkers:
7.2.1. Circulating Tumor Cells (CTC)
7.2.2. Circulating Tumor DNA (ctDNA)
7.2.3. Exosomes (Macrovesicles with Protein, RNA, DNA)
CHAPTER 8. MARKET CATEGORIZATION 4: TECHNOLOGY ESTIMATES & TREND ANALYSIS
8.1. Technology Movement Analysis & Market Share, 2015, 2020 & 2030
8.2. Market Size & Forecasts and Trend Analyses, 2013 to 2030 for the following technologies:
8.2.1. Multi-gene parallel Analysis using NGS
8.2.2. Single Gene Analysis using PCR Microarrays
CHAPTER 9. MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Movement Analysis & Market Share, 2015, 2020 & 2030
9.2. North America
9.2.1. North America revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. North America revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.2.2.1. U.S.
9.2.2.2. Canada
9.2.3. North America revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.2.3.1. U.S.
9.2.3.2. Canada
9.2.4. North America revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.2.4.1. U.S.
9.2.4.2. Canada
9.3. Europe
9.3.1. Europe revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.3.1.1. Germany
9.3.1.2. UK
9.3.2. Europe revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.3.2.1. Germany
9.3.2.2. UK
9.3.3. Europe revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.3.3.1. Germany
9.3.3.2. UK
9.3.4. Europe revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.3.4.1. Germany
9.3.4.2. UK
9.4. Asia Pacific
9.4.1. Asia Pacific revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.4.1.1. Japan
9.4.1.2. China
9.4.2. Asia Pacific revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.4.2.1. Japan
9.4.2.2. China
9.4.3. Asia Pacific revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.4.3.1. Japan
9.4.3.2. China
9.4.4. Asia Pacific revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.4.4.1. Japan
9.4.4.2. China
9.5. Latin America
9.5.1. Latin America revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.5.1.1. Brazil
9.5.2. Latin America revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.5.2.1. Brazil
9.5.3. Latin America revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.5.3.1. Brazil
9.5.4. Latin America revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.5.4.1. Brazil
9.6. Middle East & Africa
9.6.1. Middle East & Africa revenue estimates and forecasts by application, 2013 - 2030 (USD Million)
9.6.1.1. South Africa
9.6.2. Middle East & Africa revenue estimates and forecasts by sample type, 2013 - 2030 (USD Million)
9.6.2.1. South Africa
9.6.3. Middle East & Africa revenue estimates and forecasts by biomarker, 2013 - 2030 (USD Million)
9.6.3.1. South Africa
9.6.4. Middle East & Africa revenue estimates and forecasts by technology, 2013 - 2030 (USD Million)
9.6.4.1. South Africa
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Adaptive Biotechnologies
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiatives
10.2. Biocept
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Strategic Initiatives
10.3. Guardant Health
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Strategic Initiatives
10.4. NeoGenomics Laboratories
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Strategic Initiatives
10.5. Personal Genome Diagnostics
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Strategic Initiatives
10.6. Qiagen
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Strategic Initiatives
10.7. RainDance Technologies
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Strategic Initiatives
10.8. Trovagene
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Strategic Initiatives
10.9. Cynvenio
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Strategic Initiatives
10.10. Epic Sciences
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Strategic Initiatives
10.11. Exosome
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Strategic Initiatives
10.12. Foundation Medicine
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Strategic Initiatives
10.13. Genomic Health
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Strategic Initiatives
10.14. Illumina Inc.
10.14.1. Company Overview
10.14.2. Financial Performance
10.14.4. Strategic Initiatives
10.15. Angle Plc
10.15.1. Company Overview
10.15.2. Financial Performance
10.15.3. Product Benchmarking
10.15.4. Strategic Initiatives
10.16. Boreal Genomics
10.16.1. Company Overview
10.16.2. Financial Performance
10.16.3. Product Benchmarking
10.16.4. Strategic Initiatives
10.17. CareDx
10.17.1. Company Overview
10.17.2. Financial Performance
10.17.3. Product Benchmarking
10.17.4. Strategic Initiatives
10.18. Chronix Biomedical
10.18.1. Company Overview
10.18.2. Financial Performance
10.18.3. Product Benchmarking
10.18.4. Strategic Initiatives
10.19. Cynvenio Biosystems Inc.
10.19.1. Company Overview
10.19.2. Financial Performance
10.19.3. Product Benchmarking
10.19.4. Strategic Initiatives
10.20. Epic Sciences
10.20.1. Company Overview
10.20.2. Financial Performance
10.20.3. Product Benchmarking
10.20.4. Strategic Initiatives
10.21. Foundation Medicine
10.21.1. Company Overview
10.21.2. Financial Performance
10.21.3. Product Benchmarking
10.21.4. Strategic Initiatives
10.22. Natera Inc.
10.22.1. Company Overview
10.22.2. Financial Performance
10.22.3. Product Benchmarking
10.22.4. Strategic Initiatives
10.23. Pathway Genomics
10.23.1. Company Overview
10.23.2. Financial Performance
10.23.3. Product Benchmarking
10.23.4. Strategic Initiatives
10.24. Roche (Ariosa)
10.24.1. Company Overview
10.24.2. Financial Performance
10.24.3. Product Benchmarking
10.24.4. Strategic Initiatives
10.25. Sequenom
10.25.1. Company Overview
10.25.2. Financial Performance
10.25.3. Product Benchmarking
10.25.4. Strategic Initiatives
10.26. Trovagene
10.26.1. Company Overview
10.26.2. Financial Performance
10.26.3. Product Benchmarking
10.26.4. Strategic Initiatives
LIST OF TABLES
Table 1. North America liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 2. North America liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 3. North America liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 4. North America liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 5. U.S. liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 6. U.S. liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 7. U.S. liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 8. U.S. liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 9. Canada liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 10. Canada liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 11. Canada liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 12. Canada liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 13. Europe liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 14. Europe liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 15. Europe liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 16. Europe liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 17. Germany liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 18. Germany liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 19. Germany liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 20. Germany liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 21. UK liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 22. UK liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 23. UK liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 24. UK liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 25. Asia Pacific liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 26. Asia Pacific liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 27. Asia Pacific liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 28. Asia Pacific liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 29. Japan liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 30. Japan liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 31. Japan liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 32. Japan liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 33. China liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 34. China liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 35. China liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 36. China liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 37. Latin America liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 38. Latin America liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 39. Latin America liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 40. Latin America liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 41. Brazil liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 42. Brazil liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 43. Brazil liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 44. Brazil liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 45. MEA liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 46. MEA liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 47. MEA liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 48. MEA liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 49. South Africa liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 50. South Africa liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 51. South Africa liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 52. South Africa liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 1. North America liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 2. North America liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 3. North America liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 4. North America liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 5. U.S. liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 6. U.S. liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 7. U.S. liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 8. U.S. liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 9. Canada liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 10. Canada liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 11. Canada liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 12. Canada liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 13. Europe liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 14. Europe liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 15. Europe liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 16. Europe liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 17. Germany liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 18. Germany liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 19. Germany liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 20. Germany liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 21. UK liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 22. UK liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 23. UK liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 24. UK liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 25. Asia Pacific liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 26. Asia Pacific liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 27. Asia Pacific liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 28. Asia Pacific liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 29. Japan liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 30. Japan liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 31. Japan liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 32. Japan liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 33. China liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 34. China liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 35. China liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 36. China liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 37. Latin America liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 38. Latin America liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 39. Latin America liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 40. Latin America liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 41. Brazil liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 42. Brazil liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 43. Brazil liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 44. Brazil liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 45. MEA liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 46. MEA liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 47. MEA liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 48. MEA liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
Table 49. South Africa liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
Table 50. South Africa liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
Table 51. South Africa liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
Table 52. South Africa liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1. Market research process
Fig. 2. Information procurement
Fig. 3. Primary research pattern
Fig. 4. Market research approaches
Fig. 5. Value chain based sizing & forecasting
Fig. 6. Market summary
Fig. 7. Market trends & outlook
Fig. 8. Market segmentation & scope
Fig. 9. Market driver relevance analysis (current & future impact)
Fig. 10. Market restraint relevance analysis (current & future impact)
Fig. 11. Penetration & growth prospect mapping, 2015 - 2030
Fig. 12. SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 13. Porter’s Five Forces Analysis
Fig. 14. Liquid biopsy market: Application outlook key takeaways
Fig. 15. Liquid biopsy market: Application movement analysis
Fig. 16. Global therapy selection for MBS market, 2013 - 2030 (USD Million)
Fig. 17. Global therapy selection for other metastatic cancer market, 2013 - 2030 (USD Million)
Fig. 18. Global molecular monitoring market, 2013 - 2030 (USD Million)
Fig. 19. Liquid biopsy market: Sample type outlook key takeaways
Fig. 20. Liquid biopsy market: Sample type movement analysis
Fig. 21. Global blood sample based market, 2013 - 2030 (USD Million)
Fig. 22. Global urine sample based market, 2013 - 2030 (USD Million)
Fig. 23. Global other bio fluid (tissue fluid and saliva) sample based market, 2013 - 2030 (USD Million)
Fig. 24. Liquid biopsy market: biomarker outlook key takeaways
Fig. 25. Liquid biopsy market: biomarker movement analysis
Fig. 26. Global CTC based liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 27. Global ctDNA based liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 28. Global exosomes based liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 29. Liquid biopsy market: Technology outlook key takeaways
Fig. 30. Liquid biopsy market: Technology movement analysis
Fig. 31. Global multi-gene analysis using NGS market, 2013 - 2030 (USD Million)
Fig. 32. Global single gene analysis using PCR microarrays market, 2013 - 2030 (USD Million)
Fig. 33. Regional market place: Key takeaway
Fig. 34. Liquid biopsy market regional outlook, 2015 & 2024
Fig. 35. North America liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 36. U.S. liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 37. Canada liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 38. Europe liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 39. Germany liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 40. UK liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 41. Asia Pacific liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 42. Japan liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 43. China liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 44. Latin America liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 45. Brazil liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 46. MEA liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 47. South Africa liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 48. Strategy framework
Fig. 49. Participant categorization
Fig. 1. Market research process
Fig. 2. Information procurement
Fig. 3. Primary research pattern
Fig. 4. Market research approaches
Fig. 5. Value chain based sizing & forecasting
Fig. 6. Market summary
Fig. 7. Market trends & outlook
Fig. 8. Market segmentation & scope
Fig. 9. Market driver relevance analysis (current & future impact)
Fig. 10. Market restraint relevance analysis (current & future impact)
Fig. 11. Penetration & growth prospect mapping, 2015 - 2030
Fig. 12. SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 13. Porter’s Five Forces Analysis
Fig. 14. Liquid biopsy market: Application outlook key takeaways
Fig. 15. Liquid biopsy market: Application movement analysis
Fig. 16. Global therapy selection for MBS market, 2013 - 2030 (USD Million)
Fig. 17. Global therapy selection for other metastatic cancer market, 2013 - 2030 (USD Million)
Fig. 18. Global molecular monitoring market, 2013 - 2030 (USD Million)
Fig. 19. Liquid biopsy market: Sample type outlook key takeaways
Fig. 20. Liquid biopsy market: Sample type movement analysis
Fig. 21. Global blood sample based market, 2013 - 2030 (USD Million)
Fig. 22. Global urine sample based market, 2013 - 2030 (USD Million)
Fig. 23. Global other bio fluid (tissue fluid and saliva) sample based market, 2013 - 2030 (USD Million)
Fig. 24. Liquid biopsy market: biomarker outlook key takeaways
Fig. 25. Liquid biopsy market: biomarker movement analysis
Fig. 26. Global CTC based liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 27. Global ctDNA based liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 28. Global exosomes based liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 29. Liquid biopsy market: Technology outlook key takeaways
Fig. 30. Liquid biopsy market: Technology movement analysis
Fig. 31. Global multi-gene analysis using NGS market, 2013 - 2030 (USD Million)
Fig. 32. Global single gene analysis using PCR microarrays market, 2013 - 2030 (USD Million)
Fig. 33. Regional market place: Key takeaway
Fig. 34. Liquid biopsy market regional outlook, 2015 & 2024
Fig. 35. North America liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 36. U.S. liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 37. Canada liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 38. Europe liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 39. Germany liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 40. UK liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 41. Asia Pacific liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 42. Japan liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 43. China liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 44. Latin America liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 45. Brazil liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 46. MEA liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 47. South Africa liquid biopsy market, 2013 - 2030 (USD Million)
Fig. 48. Strategy framework
Fig. 49. Participant categorization
